Molecular Partners Ag Stock Performance
| MLLCF Stock | USD 3.50 0.55 13.58% |
Molecular Partners has a performance score of 1 on a scale of 0 to 100. The company secures a Beta (Market Risk) of -0.35, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Molecular Partners are expected to decrease at a much lower rate. During the bear market, Molecular Partners is likely to outperform the market. Molecular Partners right now secures a risk of 2.64%. Please verify Molecular Partners AG total risk alpha, as well as the relationship between the daily balance of power and day typical price , to decide if Molecular Partners AG will be following its current price movements.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Molecular Partners AG are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite nearly stable fundamental indicators, Molecular Partners is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 133.7 M | |
| Total Cashflows From Investing Activities | -22.2 M |
Molecular |
Molecular Partners Relative Risk vs. Return Landscape
If you would invest 350.00 in Molecular Partners AG on September 28, 2025 and sell it today you would earn a total of 0.00 from holding Molecular Partners AG or generate 0.0% return on investment over 90 days. Molecular Partners AG is currently producing 0.0342% returns and takes up 2.6444% volatility of returns over 90 trading days. Put another way, 23% of traded pink sheets are less volatile than Molecular, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Molecular Partners Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Molecular Partners' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Molecular Partners AG, and traders can use it to determine the average amount a Molecular Partners' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0129
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MLLCF |
Based on monthly moving average Molecular Partners is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Molecular Partners by adding it to a well-diversified portfolio.
Molecular Partners Fundamentals Growth
Molecular Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Molecular Partners, and Molecular Partners fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Molecular Pink Sheet performance.
| Return On Equity | 0.62 | |||
| Return On Asset | 0.32 | |||
| Profit Margin | 0.62 % | |||
| Operating Margin | 0.61 % | |||
| Current Valuation | (41.92 M) | |||
| Shares Outstanding | 36.04 M | |||
| Price To Earning | 1.74 X | |||
| Price To Book | 0.91 X | |||
| Price To Sales | 1.19 X | |||
| Revenue | 9.33 M | |||
| EBITDA | (60.67 M) | |||
| Cash And Equivalents | 267.13 M | |||
| Cash Per Share | 8.22 X | |||
| Total Debt | 5.15 M | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 7.73 X | |||
| Cash Flow From Operations | (90.95 M) | |||
| Earnings Per Share | 3.82 X | |||
| Total Asset | 172.67 M | |||
About Molecular Partners Performance
By analyzing Molecular Partners' fundamental ratios, stakeholders can gain valuable insights into Molecular Partners' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Molecular Partners has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Molecular Partners has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland. MOLECULAR PARTNERS operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 163 people.Things to note about Molecular Partners performance evaluation
Checking the ongoing alerts about Molecular Partners for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Molecular Partners help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the revenue of 9.33 M. Net Loss for the year was (63.78 M) with loss before overhead, payroll, taxes, and interest of (45.96 M). | |
| Molecular Partners AG has accumulated about 267.13 M in cash with (90.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 14.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Molecular Partners' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Molecular Partners' stock is overvalued or undervalued compared to its peers.
- Examining Molecular Partners' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Molecular Partners' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Molecular Partners' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Molecular Partners' pink sheet. These opinions can provide insight into Molecular Partners' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Molecular Pink Sheet analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |